Incretin-based Therapy in Chronic Kidney Disease

被引：8
作者：
Pinelli, Nicole R. [1 ]
Moore, Carol L.
Tomasello, Sarah
机构：
[1] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Dept Pharm Practice, Detroit, MI 48201 USA
来源：
ADVANCES IN CHRONIC KIDNEY DISEASE | 2010年 / 17卷 / 05期
关键词：
Diabetes mellitus; Chronic kidney disease; End stage renal disease; Incretins; Glucagon like peptide-1; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; GLUCAGON-LIKE PEPTIDE-1; IMPROVES GLYCEMIC CONTROL; DOUBLE-BLIND; METFORMIN THERAPY; RENAL IMPAIRMENT; HEALTHY-SUBJECTS; GLP-1; ANALOG; SITAGLIPTIN; SAFETY;
D O I：
10.1053/j.ackd.2010.06.003
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Type 2 diabetes mellitus (T2DM) with concomitant CKD is an emerging clinical and public health problem reaching epidemic proportions in the United States. Achieving and maintaining glycemic targets in clinical practice are significant challenges in majority of the patients with T2DM and CKD, and this has created significant barriers for clinicians managing these patients. Commonly used antihyperglycemic agents are either contraindicated or lack efficacy and safety information in this population. Recently, 2 distinct classes of agents that augment incretin hormone action have been added to the therapeutic armamentarium targeting hyperglycemia. This review will discuss the literature examining the efficacy and safety of incretin-based therapies in T2DM and the available evidence for their use in CKD. (C) 2010 by the National Kidney Foundation, Inc. All rights reserved.
引用
收藏
页码：439 / 449
页数：11
相关论文
共 58 条
[21]   Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption [J].
Guan, YF ;
Hao, CM ;
Cha, DR ;
Rao, R ;
Lu, WD ;
Kohan, DE ;
Magnuson, MA ;
Redha, R ;
Zhang, YH ;
Breyer, MD .
NATURE MEDICINE, 2005, 11 (08) :861-866
[22]   Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men [J].
Gutzwiller, JP ;
Tschopp, S ;
Bock, A ;
Zehnder, CE ;
Huber, AR ;
Kreyenbuehl, M ;
Gutmann, H ;
Drewe, J ;
Henzen, C ;
Goeke, B ;
Beglinger, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (06) :3055-3061
[23]   Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses [J].
Herman, GA ;
Stevens, C ;
Van Dyck, K ;
Bergman, A ;
Yi, BM ;
De Smet, M ;
Snyder, E ;
Hilliard, D ;
Tanen, M ;
Tanaka, W ;
Wang, AQ ;
Zeng, W ;
Musson, D ;
Winchell, G ;
Davies, MJ ;
Ramael, S ;
Gottesdiener, KM ;
Wagner, JA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (06) :675-688
[24]   Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin [J].
Hermansen, K. ;
Kipnes, M. ;
Luo, E. ;
Fanurik, D. ;
Khatami, H. ;
Stein, P. .
DIABETES OBESITY & METABOLISM, 2007, 9 (05) :733-745
[25]   Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone [J].
Hollander, Priscilla ;
Li, Jia ;
Allen, Elsie ;
Chen, Roland .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (12) :4810-4819
[26]   Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial [J].
Home, Philip D. ;
Pocock, Stuart J. ;
Beck-Nielsen, Henning ;
Curtis, Paula S. ;
Gomis, Ramon ;
Hanefeld, Markolf ;
Jones, Nigel P. ;
Komajda, Michel ;
McMurray, John J. V. .
LANCET, 2009, 373 (9681) :2125-2135
[27]   Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide [J].
Jacobsen, Lisbeth V. ;
Hindsberger, Charlotte ;
Robson, Richard ;
Zdravkovic, Milan .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (06) :898-905
[28]  
Jacobson TA, 2008, MAYO CLIN PROC, V83, P687, DOI 10.4065/83.6.687
[29]   Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial [J].
Jadzinsky, M. ;
Pfuetzner, A. ;
Paz-Pacheco, E. ;
Xu, Z. ;
Allen, E. ;
Chen, R. .
DIABETES OBESITY & METABOLISM, 2009, 11 (06) :611-622
[30]   Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use [J].
Kao, D. P. ;
Kohrt, H. E. ;
Kugler, J. .
DIABETIC MEDICINE, 2008, 25 (10) :1229-1230
123456